Neoadjuvant chemotherapy for osteosarcoma of the extremity in patients in the fourth and fifth decade of life

Gaetano Bacci, Stefano Ferrari, Davide Donati, Alessandra Longhi, Franco Bertoni, Maria D I Fiore, Alessandro Comandone, Marilena Cesari, Mario Campanacci

Research output: Contribution to journalArticle

Abstract

From January 1986 to March 1993, 29 patients aged between 40 and 60 years with primary high grade osteosarcoma of the extremity were treated at Rizzoli Institute with neoadjuvant chemotherapy. Before surgery patients received cisplatin and adriamycin. Postoperatively, patients with a good histologic response received the same two drugs preoperatively used, while in case of poor response ifosfamide and etoposide were added to cisplatin and adriamycin. Twenty-five patients (86%) were surgically treated with a limb salvage, whereas 4 patients (14%) were amputated. With a median follow-up of 8 years (5-12), the 8-year event-free survival was 57% and the 8-year overall survival was 62%. No chemotherapy-related deaths were recorded and toxicity was manageable. These results are significantly better than those achieved in 24 patients of the same age, treated at Rizzoli Institute between 1975 and 1985 only with surgery (87% of amputation and 17% of 8-year event-free and overall survival) and indicate an advantage for the use of neo-adjuvant chemotherapy also in patients with high grade osteosarcoma of the extremity older than 40 years.

Original languageEnglish
Pages (from-to)1259-1263
Number of pages5
JournalOncology Reports
Volume5
Issue number5
Publication statusPublished - 1998

Fingerprint

Osteosarcoma
Extremities
Drug Therapy
Doxorubicin
Cisplatin
Disease-Free Survival
Ifosfamide
Limb Salvage
Etoposide
Adjuvant Chemotherapy
Amputation
Survival
Pharmaceutical Preparations

Keywords

  • Adult patients
  • Neoadjuvant chemotherapy
  • Osteosarcoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Bacci, G., Ferrari, S., Donati, D., Longhi, A., Bertoni, F., Fiore, M. D. I., ... Campanacci, M. (1998). Neoadjuvant chemotherapy for osteosarcoma of the extremity in patients in the fourth and fifth decade of life. Oncology Reports, 5(5), 1259-1263.

Neoadjuvant chemotherapy for osteosarcoma of the extremity in patients in the fourth and fifth decade of life. / Bacci, Gaetano; Ferrari, Stefano; Donati, Davide; Longhi, Alessandra; Bertoni, Franco; Fiore, Maria D I; Comandone, Alessandro; Cesari, Marilena; Campanacci, Mario.

In: Oncology Reports, Vol. 5, No. 5, 1998, p. 1259-1263.

Research output: Contribution to journalArticle

Bacci, G, Ferrari, S, Donati, D, Longhi, A, Bertoni, F, Fiore, MDI, Comandone, A, Cesari, M & Campanacci, M 1998, 'Neoadjuvant chemotherapy for osteosarcoma of the extremity in patients in the fourth and fifth decade of life', Oncology Reports, vol. 5, no. 5, pp. 1259-1263.
Bacci, Gaetano ; Ferrari, Stefano ; Donati, Davide ; Longhi, Alessandra ; Bertoni, Franco ; Fiore, Maria D I ; Comandone, Alessandro ; Cesari, Marilena ; Campanacci, Mario. / Neoadjuvant chemotherapy for osteosarcoma of the extremity in patients in the fourth and fifth decade of life. In: Oncology Reports. 1998 ; Vol. 5, No. 5. pp. 1259-1263.
@article{c52c9849cecd41b5bffc9d60f732db07,
title = "Neoadjuvant chemotherapy for osteosarcoma of the extremity in patients in the fourth and fifth decade of life",
abstract = "From January 1986 to March 1993, 29 patients aged between 40 and 60 years with primary high grade osteosarcoma of the extremity were treated at Rizzoli Institute with neoadjuvant chemotherapy. Before surgery patients received cisplatin and adriamycin. Postoperatively, patients with a good histologic response received the same two drugs preoperatively used, while in case of poor response ifosfamide and etoposide were added to cisplatin and adriamycin. Twenty-five patients (86{\%}) were surgically treated with a limb salvage, whereas 4 patients (14{\%}) were amputated. With a median follow-up of 8 years (5-12), the 8-year event-free survival was 57{\%} and the 8-year overall survival was 62{\%}. No chemotherapy-related deaths were recorded and toxicity was manageable. These results are significantly better than those achieved in 24 patients of the same age, treated at Rizzoli Institute between 1975 and 1985 only with surgery (87{\%} of amputation and 17{\%} of 8-year event-free and overall survival) and indicate an advantage for the use of neo-adjuvant chemotherapy also in patients with high grade osteosarcoma of the extremity older than 40 years.",
keywords = "Adult patients, Neoadjuvant chemotherapy, Osteosarcoma",
author = "Gaetano Bacci and Stefano Ferrari and Davide Donati and Alessandra Longhi and Franco Bertoni and Fiore, {Maria D I} and Alessandro Comandone and Marilena Cesari and Mario Campanacci",
year = "1998",
language = "English",
volume = "5",
pages = "1259--1263",
journal = "Oncology Reports",
issn = "1021-335X",
publisher = "Spandidos Publications",
number = "5",

}

TY - JOUR

T1 - Neoadjuvant chemotherapy for osteosarcoma of the extremity in patients in the fourth and fifth decade of life

AU - Bacci, Gaetano

AU - Ferrari, Stefano

AU - Donati, Davide

AU - Longhi, Alessandra

AU - Bertoni, Franco

AU - Fiore, Maria D I

AU - Comandone, Alessandro

AU - Cesari, Marilena

AU - Campanacci, Mario

PY - 1998

Y1 - 1998

N2 - From January 1986 to March 1993, 29 patients aged between 40 and 60 years with primary high grade osteosarcoma of the extremity were treated at Rizzoli Institute with neoadjuvant chemotherapy. Before surgery patients received cisplatin and adriamycin. Postoperatively, patients with a good histologic response received the same two drugs preoperatively used, while in case of poor response ifosfamide and etoposide were added to cisplatin and adriamycin. Twenty-five patients (86%) were surgically treated with a limb salvage, whereas 4 patients (14%) were amputated. With a median follow-up of 8 years (5-12), the 8-year event-free survival was 57% and the 8-year overall survival was 62%. No chemotherapy-related deaths were recorded and toxicity was manageable. These results are significantly better than those achieved in 24 patients of the same age, treated at Rizzoli Institute between 1975 and 1985 only with surgery (87% of amputation and 17% of 8-year event-free and overall survival) and indicate an advantage for the use of neo-adjuvant chemotherapy also in patients with high grade osteosarcoma of the extremity older than 40 years.

AB - From January 1986 to March 1993, 29 patients aged between 40 and 60 years with primary high grade osteosarcoma of the extremity were treated at Rizzoli Institute with neoadjuvant chemotherapy. Before surgery patients received cisplatin and adriamycin. Postoperatively, patients with a good histologic response received the same two drugs preoperatively used, while in case of poor response ifosfamide and etoposide were added to cisplatin and adriamycin. Twenty-five patients (86%) were surgically treated with a limb salvage, whereas 4 patients (14%) were amputated. With a median follow-up of 8 years (5-12), the 8-year event-free survival was 57% and the 8-year overall survival was 62%. No chemotherapy-related deaths were recorded and toxicity was manageable. These results are significantly better than those achieved in 24 patients of the same age, treated at Rizzoli Institute between 1975 and 1985 only with surgery (87% of amputation and 17% of 8-year event-free and overall survival) and indicate an advantage for the use of neo-adjuvant chemotherapy also in patients with high grade osteosarcoma of the extremity older than 40 years.

KW - Adult patients

KW - Neoadjuvant chemotherapy

KW - Osteosarcoma

UR - http://www.scopus.com/inward/record.url?scp=0031877967&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031877967&partnerID=8YFLogxK

M3 - Article

C2 - 9683847

AN - SCOPUS:0031877967

VL - 5

SP - 1259

EP - 1263

JO - Oncology Reports

JF - Oncology Reports

SN - 1021-335X

IS - 5

ER -